Foghorn Therapeutics Inc. Increase (Decrease) in Contract with Customer, Liability
Foghorn Therapeutics Inc. (FHTX) reported Increase (Decrease) in Contract with Customer, Liability of -$19.34 million for the 6-month period ending 2026-06-30, per its 10-Q filed 2026-08-06.
Financial Statements › Cash Flow › Operating Activities
us-gaap:IncreaseDecreaseInContractWithCustomerLiability · last filed 2026-08-06
- Foghorn Therapeutics Inc. increase (decrease) in contract with customer, liability for the quarter ending 2026-06-30 was -$16.07M.
- Foghorn Therapeutics Inc. increase (decrease) in contract with customer, liability for the quarter ending 2026-03-31 was -$3.27M.
- Foghorn Therapeutics Inc. increase (decrease) in contract with customer, liability for the quarter ending 2025-12-31 was -$9.25M.
- Foghorn Therapeutics Inc. increase (decrease) in contract with customer, liability for the quarter ending 2025-09-30 was -$8.15M.
- Foghorn Therapeutics Inc. increase (decrease) in contract with customer, liability for fiscal 2025 was -$30.91M.
- Foghorn Therapeutics Inc. increase (decrease) in contract with customer, liability for fiscal 2024 was -$22.60M.
- Foghorn Therapeutics Inc. increase (decrease) in contract with customer, liability for fiscal 2023 was -$34.16M.
- Foghorn Therapeutics Inc. increase (decrease) in contract with customer, liability for fiscal 2022 was -$14.23M, a 104.23% decline from fiscal 2021.
| Period end | Increase (Decrease) in Contract with Customer, Liability 3 month | Increase (Decrease) in Contract with Customer, Liability 6 month | Increase (Decrease) in Contract with Customer, Liability 9 month | Increase (Decrease) in Contract with Customer, Liability 12 month |
|---|---|---|---|---|
| 2026-06-30 | -$16.07M derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-06 | -$19.34M 10-Q · filed 2026-08-06 | -$28.59M derived: sum of 3 quarters · filed 2026-08-06 | -$36.74M derived: sum of 4 quarters · filed 2026-08-06 |
| 2026-03-31 | -$3.27M 10-Q · filed 2026-05-07 | -$12.51M derived: sum of 2 quarters · filed 2026-05-07 | -$20.67M derived: sum of 3 quarters · filed 2026-05-07 | -$28.23M derived: sum of 4 quarters · filed 2026-08-06 |
| 2025-12-31 | -$9.25M derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-11 | -$17.40M derived: sum of 2 quarters · filed 2026-03-11 | -$24.96M derived: sum of 3 quarters · filed 2026-08-06 | -$30.91M 10-K · filed 2026-03-11 |
| 2025-09-30 | -$8.15M derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-05 | -$15.71M derived: sum of 2 quarters · filed 2026-08-06 | -$21.66M 10-Q · filed 2025-11-05 | -$24.52M derived: sum of 4 quarters · filed 2026-08-06 |
| 2025-06-30 | -$7.56M derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-06 | -$13.51M 10-Q · filed 2026-08-06 | -$16.36M derived: sum of 3 quarters · filed 2026-08-06 | -$24.17M derived: sum of 4 quarters · filed 2026-08-06 |
| 2025-03-31 | -$5.95M 10-Q · filed 2026-05-07 | -$8.81M derived: sum of 2 quarters · filed 2026-05-07 | -$16.61M derived: sum of 3 quarters · filed 2026-05-07 | -$23.50M derived: sum of 4 quarters · filed 2026-05-07 |
| 2024-12-31 | -$2.86M derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-11 | -$10.66M derived: sum of 2 quarters · filed 2026-03-11 | -$17.55M derived: sum of 3 quarters · filed 2026-03-11 | -$22.60M 10-K · filed 2026-03-11 |
| 2024-09-30 | -$7.81M derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-05 | -$14.70M derived: sum of 2 quarters · filed 2025-11-05 | -$19.75M 10-Q · filed 2025-11-05 | -$25.52M derived: sum of 4 quarters · filed 2025-11-05 |
| 2024-06-30 | -$6.89M derived: 10-Q 6 month − 10-Q 3 month · filed 2025-08-05 | -$11.94M 10-Q · filed 2025-08-05 | -$17.71M derived: sum of 3 quarters · filed 2025-08-05 | -$35.19M derived: sum of 4 quarters · filed 2025-08-05 |
| 2024-03-31 | -$5.05M 10-Q · filed 2025-05-14 | -$10.82M derived: sum of 2 quarters · filed 2025-05-14 | -$28.30M derived: sum of 3 quarters · filed 2025-05-14 | -$33.90M derived: sum of 4 quarters · filed 2025-05-14 |
| 2023-12-31 | -$5.77M derived: 10-K 12 month − 10-Q 9 month · filed 2025-03-06 | -$23.25M derived: sum of 2 quarters · filed 2025-03-06 | -$28.85M derived: sum of 3 quarters · filed 2025-03-06 | -$34.16M 10-K · filed 2025-03-06 |
| 2023-09-30 | -$17.48M derived: 10-Q 9 month − 10-Q 6 month · filed 2024-11-04 | -$23.08M derived: sum of 2 quarters · filed 2024-11-04 | -$28.39M 10-Q · filed 2024-11-04 | -$32.57M derived: sum of 4 quarters · filed 2024-11-04 |
| 2023-06-30 | -$5.60M derived: 10-Q 6 month − 10-Q 3 month · filed 2024-08-08 | -$10.91M 10-Q · filed 2024-08-08 | -$15.09M derived: sum of 3 quarters · filed 2024-08-08 | -$16.73M derived: sum of 4 quarters · filed 2024-08-08 |
| 2023-03-31 | -$5.31M 10-Q · filed 2024-05-06 | -$9.49M derived: sum of 2 quarters · filed 2024-05-06 | -$11.13M derived: sum of 3 quarters · filed 2024-05-06 | -$15.62M derived: sum of 4 quarters · filed 2024-05-06 |
| 2022-12-31 | -$4.18M derived: 10-K 12 month − 10-Q 9 month · filed 2024-03-07 | -$5.82M derived: sum of 2 quarters · filed 2024-03-07 | -$10.31M derived: sum of 3 quarters · filed 2024-03-07 | -$14.23M 10-K · filed 2024-03-07 |
| 2022-09-30 | -$1.63M derived: 10-Q 9 month − 10-Q 6 month · filed 2023-11-02 | -$6.12M derived: sum of 2 quarters · filed 2023-11-02 | -$10.04M 10-Q · filed 2023-11-02 | $327.04M derived: sum of 4 quarters · filed 2023-11-02 |
| 2022-06-30 | -$4.49M derived: 10-Q 6 month − 10-Q 3 month · filed 2023-08-04 | -$8.41M 10-Q · filed 2023-08-04 | $328.67M derived: sum of 3 quarters · filed 2023-08-04 | $328.63M derived: sum of 4 quarters · filed 2023-08-04 |
| 2022-03-31 | -$3.92M 10-Q · filed 2023-05-08 | $333.16M derived: sum of 2 quarters · filed 2023-05-08 | $333.12M derived: sum of 3 quarters · filed 2023-05-08 | $332.84M derived: sum of 4 quarters · filed 2023-05-08 |
| 2021-12-31 | $337.08M derived: 10-K 12 month − 10-Q 9 month · filed 2023-03-09 | $337.04M derived: sum of 2 quarters · filed 2023-03-09 | $336.76M derived: sum of 3 quarters · filed 2023-03-09 | $336.48M 10-K · filed 2023-03-09 |
| 2021-09-30 | -$41.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2022-11-08 | -$320.00K derived: sum of 2 quarters · filed 2022-11-08 | -$606.00K 10-Q · filed 2022-11-08 | -$857.00K derived: sum of 4 quarters · filed 2022-11-08 |
| 2021-06-30 | -$279.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2022-08-09 | -$565.00K 10-Q · filed 2022-08-09 | -$816.00K derived: sum of 3 quarters · filed 2022-08-09 | $14.01M derived: sum of 4 quarters · filed 2022-08-09 |
| 2021-03-31 | -$286.00K 10-Q · filed 2022-05-09 | -$537.00K derived: sum of 2 quarters · filed 2022-08-09 | $14.28M derived: sum of 3 quarters · filed 2022-08-09 | $14.28M derived: sum of 4 quarters · filed 2022-08-09 |
| 2020-12-31 | -$251.00K derived: 10-K/A 12 month − 10-Q 9 month · filed 2022-08-09 | $14.57M derived: sum of 2 quarters · filed 2022-08-09 | $14.57M derived: sum of 3 quarters · filed 2022-08-09 | $14.57M 10-K/A · filed 2022-08-09 |
| 2020-09-30 | $14.82M derived: 10-Q 9 month − 10-Q 6 month · filed 2021-11-09 | $14.82M derived: sum of 2 quarters · filed 2021-11-09 | $14.82M 10-Q · filed 2021-11-09 | |
| 2020-06-30 | $0.00 derived: 10-Q 6 month − 10-Q 3 month · filed 2021-08-10 | $0.00 10-Q · filed 2021-08-10 | ||
| 2020-03-31 | $0.00 10-Q · filed 2021-05-11 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Eledon Pharmaceuticals, Inc. (ELDN) | United States | $0.219B | -3.23 |
| Whitehawk Therapeutics, Inc. (WHWK) | United States | $0.221B | |
| Nkarta, Inc. (NKTX) | United States | $0.205B | -1.73 |
| NATURES SUNSHINE PRODUCTS INC (NATR) | United States | $0.228B | 20.51 |
| ORAMED PHARMACEUTICALS INC. (ORMP) | $0.199B | 1.13 | |
| Keros Therapeutics, Inc. (KROS) | United States | $0.229B | -2.55 |
| Zentalis Pharmaceuticals, Inc. (ZNTL) | United States | $0.196B | -2.48 |
| Cartesian Therapeutics, Inc. (RNAC) | United States | $0.231B | -2.04 |
| SIGA TECHNOLOGIES INC (SIGA) | United States | $0.234B | -93.33 |
| Sionna Therapeutics, Inc. (SION) | United States | $0.236B | -20.37 |